Challenges of Multidrug-Resistant Organisms in CF Lung Disease

Volume 8, Issue 3

Challenges of Multidrug-Resistant Organisms in CF Lung Disease

In this issue:

Pseudomonas aeruginosa (Pa), one of the most common chronic infections among people with CF, has a variety of innate and adaptive mechanisms that have allowed it to become increasingly multidrug-resistant (MDR). MDR Pa, as well as other MDR organisms in the CF lung, are associated with increased morbidity and mortality and have become a growing threat to cystic fibrosis patients worldwide.

In this issue, Dr. Claire Elson, a Pulmonary Medicine/Cystic Fibrosis Clinical Pharmacy Specialist from the University of Missouri–Kansas City School of Pharmacy, and Dr. Christopher Oermann, Cystic Fibrosis Care Center Director and Professor of Pediatrics at the UMKC School of Medicine, review the current literature describing the changing epidemiology of MDR infections, the mechanisms of MDR development in Pseudomonas aeruginosa, and potential treatment strategies.

Learning objective:

• Discuss the changing epidemiology of multidrug-resistant infections in people with cystic fibrosis.

• Summarize the mechanisms of multidrug-resistance development in Pseudomonas aeruginosa infection in people with cystic fibrosis.

• Describe potential treatment strategies for managing multidrug-resistant Pseudomonas aeruginosa in people with cystic fibrosis.

Authors:

E. Claire Elson, PharmD, BCPPS

Clinical Pharmacy Specialist, Pulmonary Medicine/Cystic Fibrosis
Children’s Mercy Kansas City
UMKC School of Pharmacy
Adjunct Professor, University of Missouri-Kansas City School of Pharmacy
Kansas City, MO

Christopher Oermann, MD

Division Director, Division of Pulmonary and Sleep Medicine
Center Director, Cystic Fibrosis Care Center
Children's Mercy Kansas City
Kansas City, MO

Guest Faculty Disclosures

Dr. Elson has disclosed that she has served as a pharmacist advisory board member for Vertex Pharmaceuticals and Gilead Sciences.

Dr. Oermann has indicated that he has no financial interests or relationships with a commercial entity whose products or services are relevant to the content of this presentation.

Unlabeled/Unapproved Uses

Drs. Christopher Oermann & Claire Elson have indicated that there will be references to the unlabeled/unapproved use of ceftazidime, colistimethate, meropenem, aztreonam, piperacillin/tazobactam, moxifloxacin, levofloxacin and aminoglycosides (tobramycin, gentamicin and amikacin).

Program Directors:

Peter J. Mogayzel, Jr., MD, PhD

Professor of Pediatrics
Director, Cystic Fibrosis Center
Johns Hopkins University School of Medicine
Baltimore, MD

Noah Lechtzin, MD, MHA

Director, Adult Cystic Fibrosis Program
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Suzanne Sullivan, RN, BSN

Senior Clinical Nurse
The Johns Hopkins University
Baltimore, MD

Guest Faculty Disclosures:

Dr. Elson has disclosed that she has served as a pharmacist advisory board member for Vertex Pharmaceuticals and Gilead Sciences.

Dr. Oermann has indicated that he has no financial interests or relationships with a commercial entity whose products or services are relevant to the content of this presentation.

Unlabeled/Unapproved Uses:

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: December 15, 2018
Expiration date: December 14, 2020

Start Issue